Intervention

Surveillance

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting1

Common conditions5

Lead sponsors shown4

Clinical trials

4 shown

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialNCT07288034 · 2026-04-08

Ketogenic Diet and Prostate Cancer Surveillance PilotNCT03194516 · 2017-06-12

Evaluate the Efficacy of a Global Dental Health Promotion Program on Dental Hygiene in Patients With Schizophrenia.NCT02512367 · 2017-04-20

Non-systemic Treatment for Patients With Low-volume Metastatic Prostate CancerNCT01558427 · 2012-08-01

Common conditions

Prostate Cancer2 Lung Non-Small Cell Carcinoma1 Schizophrenia1 Stage IIIB Lung Cancer AJCC v81 Stage IV Lung Cancer AJCC v81

Leading sponsors

Centre Hospitalier Universitaire Dijon1 City of Hope Medical Center1 University Hospital, Ghent1 University of Maryland, Baltimore1

Trial status mix

COMPLETED2

RECRUITING1

TERMINATED1

Phase mix

PHASE22

NA1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.